中国供应商从制造未经授权的重量损失药物转向开发合法的非专利药物。 Chinese suppliers shift from making unauthorized weight-loss drugs to developing legitimate generics.

中国供应商曾经是向美国灰色市场提供减价重量损失药品的主要供应商,现在却转而生产合法的非专利药品。 Chinese suppliers, once key providers of cut-price weight-loss drugs to the US gray market, are now shifting to making legitimate generics. 这一变化是继美国对复合药店的管制性镇压和原成分货运下降之后发生的。 This change follows US regulatory crackdowns on compounding pharmacies and a drop in raw ingredient shipments. 以前,这些供应商提供了足够的硫酸盐和tirzepatide,可生产超过10亿剂未经授权的剂量。 Previously, these suppliers provided enough semaglutide and tirzepatide to produce over a billion unauthorized doses. 现在，这些成分从中国出货量急剧下降，索马鲁肽下降了 90%，替泽帕肽下降了 34%。 Now, shipments of these ingredients from China have fallen dramatically, with semaglutide down 90% and tirzepatide down 34%. 现在至少有8家中国公司正在开发自己的专利,因为专利在加拿大和巴西等市场过期。 At least eight Chinese companies are now developing their own generics as patents expire in markets like Canada and Brazil.